Protagonist Logo. Click to navigate to a home page

Amgen tipped to keep Otezla market share in fight with BMS' Sotyktu, leaving opportunity for J&J

By Nick Paul Taylor | September 5, 2023

Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at Spherix Global Insights, who found Amgen is holding on to its market share and largely limiting BMS’ growth to the conversion of users of injectable biologics.

CONTINUE READING
Share by: